Clinical characteristics of patients in Studies of Left Ventricular Dysfunction (SOLVD)

Johnstone, David E.; Limacher, Marian C.; Rousseau, Michel F.; Liang, Chang‐seng; Ekelund, Lars‐Göran; Herman, Michael V.; Stewart, David G.; Guillotte, Maureen; Bjerken, Gina; Gaasch, William H.; Held, Peter; Verter, Joel; Stewart, Dawn; Yusuf, Salim

doi:10.1016/0002-9149(92)90734-g

Cited by 113 publications

(60 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the SOLVD trial [12], women with HF were more likely to have diabetes than men (49.3% vs 37.2%, P < 0.02). In the Framingham data, both diabetic men and women had a greater incidence of HF, but women had a much greater PAR (12% vs 6%).…”

Section: Epidemiology and Etiologymentioning

confidence: 98%

“…Assessed in this way, hypertension contributed 59% of the PAR for developing HF in women, versus 39% for men. In the Studies of Left Ventricular Dysfunction (SOLVD) treatment trial [12], women were also more likely to have a history of hypertension. It is also relevant that the Framingham and SOLVD populations were predominantly white.…”

Section: Epidemiology and Etiologymentioning

confidence: 99%

See 1 more Smart Citation

Sex differences in the causes and natural history of heart failure

Hoppe

Hermann

2003

Curr Cardiol Rep

View full text Add to dashboard Cite

Heart failure is a clinical syndrome of increasing prevalence in the United States, with significant morbidity and mortality. Although men have a higher annual mortality rate, more women than men die from heart failure each year. Optimal disease management is critical in limiting the impact of heart failure on life quality, quantity, and health care expenditures. Women have a unique risk-factor profile and different clinical manifestations of heart failure than men. Understanding inherent sex differences in heart failure epidemiology, pathophysiology, and natural history is imperative in determining whether the optimal therapy for this prevalent and important syndrome is affected by sex.

show abstract

Section: Epidemiology and Etiologymentioning

confidence: 98%

Section: Epidemiology and Etiologymentioning

confidence: 99%

Sex differences in the causes and natural history of heart failure

Hoppe

Hermann

2003

Curr Cardiol Rep

View full text Add to dashboard Cite

show abstract

“…7 This might not solely be due to a lower rate of coronary artery disease among women with CHF but could be due in part to sex bias in patient management or investigations. Philbin and DiSalvo 8 found that coronary angiography, exercise testing, and Holter monitoring were less likely to be performed in women.…”

Section: Clinical Profile Differencesmentioning

confidence: 99%

Sex Differences in the Prognosis of Congestive Heart Failure

et al. 2001

View full text Add to dashboard Cite

on Behalf of the CIBIS II InvestigatorsBackground-Whether female sex is associated with a better prognosis in patients with congestive heart failure (CHF) remains uncertain. The Cardiac Insufficiency Bisoprolol Study (CIBIS) II showed that bisoprolol reduced all-cause mortality and morbidity rates in CHF patients treated with diuretics and ACE inhibitors. We examined whether survival was different in men (nϭ2132) and women (nϭ515) enrolled in CIBIS II. Methods and Results-Women differed from men with regard to age, NYHA functional classification, primary cause of CHF, and risk factors such as left bundle-branch block. After adjustment for baseline differences, the probability of all-cause mortality was significantly reduced by 36% in women compared with that in men (hazard ratio 0.

show abstract

“…The treatment of LVD, even when asymptomatic, is associated with a better prognostic outcome (19). This study was performed to establish whether asymptomatic LVD (ALVD), as estimated by Nt-proBNP, is overrepresented in patients with type 2 diabetes compared with nondiabetic control subjects for both groups without overt cardiovascular disease.…”

mentioning

confidence: 99%

Elevated Plasma Levels of Nt-proBNP in Patients With Type 2 Diabetes Without Overt Cardiovascular Disease

et al. 2004

View full text Add to dashboard Cite

OBJECTIVE -The NH 2 -terminal portion of the precursor of brain natriuretic peptide (NtproBNP) has been reported to be elevated in left ventricular dysfunction. This peptide is a split product from the proBNP molecule, and its level in the circulation is not, as the mature BNP peptide, dependent on the peripheral number of BNP receptors. We aimed to test the hypothesis that asymptomatic left ventricular dysfunction (ALVD), as estimated by Nt-proBNP, would be more prevalent in patients with type 2 diabetes without overt cardiovascular disease in comparison with matched control subjects. RESEARCH DESIGN AND METHODS-The study population consisted of 253 patients with type 2 diabetes and 230 matched control subjects aged 40 -70 years without any overt heart disease from primary care centers in Western Finland and Southern Sweden. Nt-proBNP was measured in plasma by competitive enzyme immunosorbent assay.RESULTS -Patients with type 2 diabetes were shown to have higher .9]) than control subjects (302.7 pmol/l [215.4 -419.2]) (P Ͻ 0.001). Nt-proBNP levels were independently related to diabetes after adjustment for age, sex, systolic and diastolic blood pressure, BMI, heart rate, drug treatment, serum creatinine, and cystatin C.CONCLUSIONS -Our data suggest that the secretion of Nt-proBNP is increased in type 2 diabetic patients with no overt heart disease, suggesting that type 2 diabetes is associated with a higher prevalence of ALVD than hitherto thought. Nt-proBNP may thus serve as a screening instrument to select patients with type 2 diabetes who could benefit from an echocardiographical examination. Diabetes Care 27:1929 -1935, 2004T he incidence and prevalence of type 2 diabetes increases worldwide. In the adult population all over the world, the average prevalence for diabetes is estimated to be at least 4.0% (1). This figure is predicted to double until the year 2015 (2). Although microangiopathy represents a severe threat to the population with diabetes, macroangiopathy and subsequent cardiovascular disease are the major causes of morbidity and mortality in these patients. Screening for kidney and retinal complications is already an established part of routine diabetes care today, but there is no comparable reoccurring screening for cardiac complications of diabetes. This may simply be due to the lack of cost-effective methods; an echocardiographical examination is both expensive and time consuming and, therefore, not suited for screening purposes. The most evident cardiac complication is coronary atherosclerosis. Not only is the extent of coronary atherosclerosis increased, the disease becomes clinical earlier and is more generalized in the coronary tree compared with the subjects without diabetes (3). Diabetes is also more prevalent among patients with heart failure. In the Framingham study, male patients with diabetes had twice the risk and female patients five times the risk of a control population to develop heart failure (4). At least partially, this could be explained by the increase in severity and inci...

show abstract

Clinical characteristics of patients in Studies of Left Ventricular Dysfunction (SOLVD)

Cited by 113 publications

References 20 publications

Sex differences in the causes and natural history of heart failure

Sex differences in the causes and natural history of heart failure

Sex Differences in the Prognosis of Congestive Heart Failure

Elevated Plasma Levels of Nt-proBNP in Patients With Type 2 Diabetes Without Overt Cardiovascular Disease

Contact Info

Product

Resources

About